Home Contact

logo

Family

Links:






Archives:


Newsletter:

Register for our Free monthly newsletter to receive timely updated information about Parkinsons Disease directly in your email.
Email
First Name
Last Name
Zip Code

Categories:



Register for our FREE monthly newsletter to receive timely updated information about Parkinsons Disease directly in your email.

Parkinson’s Drug Can Have Major Withdrawal Effects

January 14th, 2010

I read this article today, I have written about dopamine addiction before, but the article below reaffirms my thoughts and takings.

(HealthDay News) — Reduced dosages of dopamine agonists, drugs routinely used to treat Parkinson’s disease, can cause symptoms similar to those experienced by addicts in withdrawal, such as anxiety, panic attacks, pain, dizziness and drug cravings, researchers say.

The symptoms of what the researchers have dubbed “dopamine agonist withdrawal syndrome” have been linked to a disruption in levels of dopamine in the brain, according to the study published in the Jan. 12 issue of the Archives of Neurology.

“Like cocaine and methamphetamines, dopamine agonists work by stimulating the reward pathways in the brain,” senior study author Dr. Melissa J. Nirenberg, said in a news release from Weill Cornell Medical Center.

“For this reason, it makes sense that they would engender similar withdrawal symptoms, particularly in those with high cumulative drug exposure,” explained Nirenberg, associate director of the Parkinson’s Disease and Movement Disorders Institute at New York-Presbyterian Hospital/Weill Cornell Medical Center and an assistant professor of neurology and neuroscience at Weill Cornell Medical College.

Dopamine agonists are used as an alternative to the drug L-DOPA, which can cause side effects in patients with Parkinson’s, such as involuntary movements. The dopamine agonist drugs — pramipexole (Mirapex) and ropinirole (Requip) — are also approved for treatment of restless legs syndrome.

In the study, researchers looked at the medical records of 93 people with Parkinson’s disease, 26 of whom lowered their doses of the dopamine agonist drugs. Five of these patients — 19 percent — experienced dopamine agonist withdrawal syndrome. Three of the five patients couldn’t adjust to the withdrawal symptoms and had to stay on the dopamine agonists, which can cause impulse control disorders, such as compulsive behaviors related to gambling, shopping, eating or sexual activity.

Using Facebook to Raise Parkinson’s Disease Awareness

January 14th, 2010

I recently read Focus on Cure’s most recent Facebook message and so I want to pass this on so that everyone who has a Facebook account can get involved, let me know if you have any questions.

As many of you know, Breast Cancer awareness has been popular the past few weeks, with placing of colors and numbers, and other fun ways on people’s status on Facebook. It even made it to the CNN news!!! Many of us want the same awareness for Parkinson’s Disease and Alzheimer’s Disease there for we thought of adding something different to our status for the next few days. For example, Day 1 (Wednesday 13th): round off number of people we know that have PD/Alzheimer’s (1-100), for those who ask what it means, say Stay tuned! Day 2 (Thursday 14th): (put family, friend, or self), meaning for those who has the illness, for those who ask again, say, Stay still tuned for the results!!! Day 3 (Friday 15th), final day: Everyone lists A symptom, such as (tremble, shake, memory), anything that pertains to the illness, then that evening you can post on your status the final result so they all know what you were referring to: Ex.. at the end comment: 100; Family; loss of thought process adding Parkinson’s Disease or Alzheimer’s Disease! Let’s get this awareness going!!! Thank you for your support!!!!

My Parkinson’s Disease is Live Again!

January 14th, 2010

After a short hiatus, My Parkinson’s Information will now be updated on a few times a week.  Despite that lack of updates over the last little while, our website has served as a powerful source to those seeking greater support, information, and answers to their world.  We feel luck that you’ve made us a part of your life one way or another and we look forward to sharing with your the latest information for Parkinson’s disease.

Mayo Clinic Develops Potential New Therapy To Stop The Progression Of Parkinson’s Disease

November 19th, 2008

Mayo Clinic (http://www.mayoclinic.org) researchers have developed a method to reduce the production of alpha-synuclein in the brain. Alpha-synuclein is a protein that is believed to be central to the cause of Parkinson’s disease (http://www.mayoclinic.org/parkinsons- disease). All patients with Parkinson’s disease have abnormal accumulations of alpha- synuclein protein in the brain.

The new method involves the delivery of RNA interference compounds directly to selected areas of the brain via injection. The RNA interference compounds silence the gene that produces alpha-synuclein, according to the Mayo researchers. The study was published this month in Molecular Neurodegeneration.

Parkinson’s disease is a progressive disorder that affects nerve cells in the part of the brain that controls muscle movement. Symptoms include tremor, slowed movement and rigid muscles. At least 1 million people in the U.S. are believed to have Parkinson’s disease, and 2 percent of the population can expect to develop the disease during their lifetime.

“While our research has not yet been tested on humans, we expect that these findings will lead to an effective treatment for slowing or even halting the progression of Parkinson’s disease,” says Demetrius Maraganore, M.D. (http://www.mayoclinic.org/bio/10345655.html), a Mayo Clinic neurologist.

Read the rest of this entry »

Sergey Brin and Parkinson’s Disease

September 19th, 2008

Google co-founder Sergey Brin launched a personal blog Thursday, on which he revealed he has a genetic code that has been linked to having increased chances for developing Parkinson’s disease.

In the blog, too.blogspot.com, Brin says his mother and great aunt both were diagnosed with the degenerative brain disorder. Through 23andme Inc., a genetic testing organization, both Brin and his mother found they carry the G2019S mutation, which accounts for a substantial proportion of familial Parkinson’s, he wrote.

“The exact implications of this are not entirely clear,” Brin wrote in the blog. “Nonetheless, it is clear that I have a markedly higher chance of developing Parkinson’s in my lifetime than the average person.”

Brin deduced that he has a 20 percent to 80 percent higher-than-average chance to develop the disease, depending on the study and measurements.

“This leaves me in a rather unique position. I know early in my life something I am substantially predisposed to. I now have the opportunity to adjust my life to reduce those odds (e.g., there is evidence that exercise may be protective against Parkinson’s),” he wrote. “I also have the opportunity to perform and support research into this disease long before it may affect me. And, regardless of my own health, it can help my family members as well as others.”

Brin said he will help support research into the disease.

“I feel fortunate to be in this position,” he wrote. “Until the fountain of youth is discovered, all of us will have some conditions in our old age only we don’t know what they will be. I have a better guess than almost anyone else for what ills may be mine —and I have decades to prepare for it.”

EMEA Releases Guidelines On Development Of Medicines For Parkinson’s Disease

September 8th, 2008

The European Medicines Agency (EMEA) has released two guidelines for companies developing medicines for the treatment of Alzheimer’s disease and other dementias, and for Parkinson’s disease, in the light of recent scientific progress in the understanding of these diseases and conditions.

Advances in clinical science, physiopathology and molecular biology have stimulated new interest in the development of more effective symptomatic or disease-modifying treatments, i.e. early treatments that may prevent the emergence or slow down the progression of disease. The guidelines were developed in response to the need of companies developing these new types of medicines for guidance on appropriate clinical-trial designs.

As life expectancy increases, neurodegenerative diseases and dementia will affect more and more people over the coming decades, and these guidelines are expected to help improve the availability of medicines to treat such diseases and conditions. The guidelines will come into effect on 1 February 2009.

Read the rest of this entry »

Preventing Protein Clumping Characteristic Of Parkinson’s Disease With Baker’s Yeast

August 18th, 2008

Baker's Yeast ScienceDaily (Aug. 15, 2008) — Researchers at the University of Pennsylvania School of Medicine have identified a protein from a most unlikely source — baker’s yeast — that might protect against Parkinson’s disease. More than a million Americans suffer from Parkinson’s disease, and no treatments are available that fundamentally alter the course of the condition.

By introducing the yeast protein Hsp104 into animal models of Parkinson’s disease, researchers prevented protein clumping that leads to nerve cell death characteristic of the disorder.

“Yeast express a protein called Hsp104, which is able to reverse protein aggregation,” says James Shorter, PhD, Assistant Professor of Biochemistry and Biophysics. “However, for reasons that are unclear Read the rest of this entry »